Publications and Research

Document Type


Publication Date



The SARS-CoV-2 2019 pandemic has created challenges to managing the post-infectious autoimmune consequences of a disease that leads to the high case fatality in adults and children. The spectrum of agents available to modulate and suppress the immune system in combination with other appropriate antiviral antibiotics and life support measures is reviewed. All of the agents envisioned to treat Covid-19 disorders, including a newly recognized pediatric multi-system inflammatory syndrome, impact post-infectious mechanisms in keeping with the multiplier effect of infection, immunity and inflammation known as I-Cubed (I3).


This work was originally published in the Archives of Neurology & Neurological Disorders.

This work is made available under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Included in

Public Health Commons



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.